title: [The beneficial effects of PGI2 analogue (OP-41483-alpha-CD) on hepatic dysfunction after warm ischemic damage].
abstract: The purpose of the experimental study was to investigate the beneficial effects of aPGI2 analogue (OP-41483-alpha-CD; aPGI2) on hepatic dysfunction after warm ischemia and reperfusion. Hepatic warm ischemia was produced by temporary clamping of the portal vein and hepatic artery. Experimental groups were divided into three groups: Group I; 60-minutes ischemia, Group II; 90-minutes ischemia, Group III; 90-minutes ischemia with intravenous aPGI2 (0.25 microgram/kg/min) infusion. The results were as follows: 1; In groups I and III, hepatic tissue flow showed a marked increase after reperfusion when compared to Group II. 2; Arterial ketone body ratio in Groups I and III recovered significantly faster than those of Group II. 3; The tissue total adenine-nucleotide levels in Groups I and III were significantly higher than those of Group II. 4; In the comparison of the radical intensity which was measured by ESR spectroscopy, the free radical of the hepatic venous blood was markedly generalized after reperfusion in Group II. However, production of free radical has significantly suppressed in Group III when compared to Group II. These results suggest that aPGI2-treatment might improved the ischemic damaged liver and might improve the prognosis of the transplanted patient.
authors.affiliation: First Department of Surgery, Hirosaki University School of Medicine, Japan.
authors.forename: M
authors.initials: M
authors.lastname: Sawada
mesh_terms: D000410:Alanine Transaminase / Q000097:blood; D000818:Animals; D001219:Aspartate Aminotransferases / Q000097:blood; D003505:Cyclodextrins / Q000627:therapeutic use*; D004285:Dogs; D011464:Epoprostenol / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D007511:Ischemia / Q000150:complications*; D008107:Liver Diseases / Q000188:drug therapy* / Q000503:physiopathology; D015427:Reperfusion Injury / Q000150:complications*; D047391:alpha-Cyclodextrins
chemical_list: D003505:Cyclodextrins; D005343:Fibrinolytic Agents; D047391:alpha-Cyclodextrins; C051518:OP 41483-alpha-cyclodextrin; D011464:Epoprostenol; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase